高度关注和防范医药产业风险  

High attention should be paid to guard against risks of domestic pharmaceutical industry

作　　者：王铁松[1] 吴科春[1] 杨文良[1] Wang Tiesong;Wu Kechun;Yang Wenliang(Beijing Institute for Drug Control,NMPA Key Laboratory for Research and Evaluation of Generic Drugs,Beijing Key Laboratory of Analysis and Evaluation on Chinese,Beijing 102206,China)

机构地区：[1]北京市药品检验所,国家药品监督管理局仿制药研究与评价重点实验室,中药成分分析与生物评价北京市重点实验室,北京102206

出　　处：《中国卫生法制》2020年第4期106-109,共4页China Health Law

摘　　要：目前我国医药产业存在三大风险,分别表现为国内药品供应链断裂或垄断风险,在国际上与美国相比研发差距大且对外医药贸易形式存在隐患,同时我国制药企业自身造血能力不足盈利能力下降。为此需要从政策协调,鼓励研发,注重监管科学等入手,进一步完善监管体系。There are three major risks in China’s pharmaceutical industry.The risks of domestic drug supply chain disruption or monopoly,the large gap in R&D compared with the United States,and the hidden danger in the form of foreign medicine trade are major risks of domestic pharmaceutical industry.At the same time,the income generating ability of pharmaceutical enterprises in China is insufficient and the profitability is declining.Therefore,we need to further improve the regulatory system from policy coordination,encourage research and development,and focus on regulatory science.

关 键 词：医药产业 风险 监管科学 

分 类 号：D902[政治法律—法学理论]